FDA Approved: TYSABRI — Supplemental Application (Biogen Inc.)

View source ↗

Summary

The FDA approved Biogen Inc.'s supplemental application for TYSABRI (natalizumab). This action updates the product's labeling per the submission.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease
• Multiple Sclerosis

Drugs mentioned

• Tysabri (Natalizumab)

Snippet

SUPPL AP for TYSABRI (NATALIZUMAB)